目的 采用RNA干扰沉默COMMD7基因,观察人肝癌细胞HepG2的变化,探讨其相关作用机制.方法 设计COMMD7基因的干扰RNA片段(shRNA),构建COMMD7-shRNA质粒.将肝癌细胞HepG2分为3组:空白组不做转染,control-shRNA组转染空载体,COMMD7-shRNA组转染阳性载体.转染结束后在荧光显微镜下观察细胞形态.采用Western blot检测COMMD7蛋白的表达.采用CCK-8检测细胞活力,流式细胞仪检测细胞凋亡.采用Western blot检测细胞外调节蛋白激酶(ERK)/丝裂原活化蛋白激酶(MAPK)信号通路中的下游分子ERK1/2和MEK1/2蛋白的表达及其磷酸化水平.符合正态分布的计量资料以(x)±s表示,多组间比较采用单因素方差分析,两两比较采用LSD-t检验.结果 荧光显微镜下转染成功的细胞为椭圆形或梭形,呈绿色荧光.Western blot检测结果显示:空白组、control-shRNA组和COMMD7-shRNA组肝癌细胞HepG2中COMMD7蛋白的相对表达量分别为0.90±0.18、1.03±0.05和0.23 ±0.03,3组比较,差异有统计学意义(F=152.08,P＜0.05);COMMD7-shRNA组COMMD7蛋白相对表达量低于空白组和control-shRNA组,两组比较,差异有统计学意义(t=20.74,21.16,P＜0.05).CCK-8检测结果显示:空白组、control-shRNA组和COMMD7-shRNA组肝癌细胞HepG2细胞活力分别为1.193±0.024、1.225±0.034和1.147 ±0.021,3组比较,差异有统计学意义(F=6.90,P＜0.05);COMMD7-shRNA组肝癌细胞HepG2细胞活力低于空白组和control-shRNA组,两组比较,差异有统计学意义(t=3.53,3.69,P＜0.05).流式细胞仪检测结果显示:空白组、control-shRNA组和COMMD7-shRNA组肝癌细胞HepG2凋亡率分别为6.1％±0.3％、7.8％±0.5％和20.9％±1.4％,3组比较,差异有统计学意义(F=270.80,P＜0.05);COMMD7-shRNA组肝癌细胞HepG2凋亡率高于空白组和control-shRNA组,两组比较,差异有统计学意义(=21.77,19.36,P＜0.05).Western blot检测结果显示:空白组、control-shRNA组和COMMD7-shRNA组肝癌细胞HepG2中磷酸化-ERK1/2蛋白相对表达量分别为0.932±0.046、0.945±0.017和0.553±0.052,磷酸化-MEK1/2蛋白相对表达量分别为0.452±0.031、0.468±0.027和0.263±0.022,3组比较,差异均有统计学意义(F =93.61,49.16,P＜0.05);COMMD7-shRNA组肝癌细胞HepG2中磷酸化-ERK1/2蛋白相对表达量低于空白组和control-shRNA组,两组比较,差异有统计学意义(t=11.94,12.17,P＜0.05);磷酸化-MEK1/2蛋白相对表达量也低于空白组和control-shRNA组,两组比较,差异有统计学意义(=9.33,8.65,P＜0.05).结论 COMMD7基因可通过活化ERK/MAPK信号通路促进肝癌细胞HepG2增殖,其作用机制可能是促进了ERK/MAPK信号通路中ERK1/2、MEK1/2的磷酸化.
目的 採用RNA榦擾沉默COMMD7基因,觀察人肝癌細胞HepG2的變化,探討其相關作用機製.方法 設計COMMD7基因的榦擾RNA片段(shRNA),構建COMMD7-shRNA質粒.將肝癌細胞HepG2分為3組:空白組不做轉染,control-shRNA組轉染空載體,COMMD7-shRNA組轉染暘性載體.轉染結束後在熒光顯微鏡下觀察細胞形態.採用Western blot檢測COMMD7蛋白的錶達.採用CCK-8檢測細胞活力,流式細胞儀檢測細胞凋亡.採用Western blot檢測細胞外調節蛋白激酶(ERK)/絲裂原活化蛋白激酶(MAPK)信號通路中的下遊分子ERK1/2和MEK1/2蛋白的錶達及其燐痠化水平.符閤正態分佈的計量資料以(x)±s錶示,多組間比較採用單因素方差分析,兩兩比較採用LSD-t檢驗.結果 熒光顯微鏡下轉染成功的細胞為橢圓形或梭形,呈綠色熒光.Western blot檢測結果顯示:空白組、control-shRNA組和COMMD7-shRNA組肝癌細胞HepG2中COMMD7蛋白的相對錶達量分彆為0.90±0.18、1.03±0.05和0.23 ±0.03,3組比較,差異有統計學意義(F=152.08,P＜0.05);COMMD7-shRNA組COMMD7蛋白相對錶達量低于空白組和control-shRNA組,兩組比較,差異有統計學意義(t=20.74,21.16,P＜0.05).CCK-8檢測結果顯示:空白組、control-shRNA組和COMMD7-shRNA組肝癌細胞HepG2細胞活力分彆為1.193±0.024、1.225±0.034和1.147 ±0.021,3組比較,差異有統計學意義(F=6.90,P＜0.05);COMMD7-shRNA組肝癌細胞HepG2細胞活力低于空白組和control-shRNA組,兩組比較,差異有統計學意義(t=3.53,3.69,P＜0.05).流式細胞儀檢測結果顯示:空白組、control-shRNA組和COMMD7-shRNA組肝癌細胞HepG2凋亡率分彆為6.1％±0.3％、7.8％±0.5％和20.9％±1.4％,3組比較,差異有統計學意義(F=270.80,P＜0.05);COMMD7-shRNA組肝癌細胞HepG2凋亡率高于空白組和control-shRNA組,兩組比較,差異有統計學意義(=21.77,19.36,P＜0.05).Western blot檢測結果顯示:空白組、control-shRNA組和COMMD7-shRNA組肝癌細胞HepG2中燐痠化-ERK1/2蛋白相對錶達量分彆為0.932±0.046、0.945±0.017和0.553±0.052,燐痠化-MEK1/2蛋白相對錶達量分彆為0.452±0.031、0.468±0.027和0.263±0.022,3組比較,差異均有統計學意義(F =93.61,49.16,P＜0.05);COMMD7-shRNA組肝癌細胞HepG2中燐痠化-ERK1/2蛋白相對錶達量低于空白組和control-shRNA組,兩組比較,差異有統計學意義(t=11.94,12.17,P＜0.05);燐痠化-MEK1/2蛋白相對錶達量也低于空白組和control-shRNA組,兩組比較,差異有統計學意義(=9.33,8.65,P＜0.05).結論 COMMD7基因可通過活化ERK/MAPK信號通路促進肝癌細胞HepG2增殖,其作用機製可能是促進瞭ERK/MAPK信號通路中ERK1/2、MEK1/2的燐痠化.
목적 채용RNA간우침묵COMMD7기인,관찰인간암세포HepG2적변화,탐토기상관작용궤제.방법 설계COMMD7기인적간우RNA편단(shRNA),구건COMMD7-shRNA질립.장간암세포HepG2분위3조:공백조불주전염,control-shRNA조전염공재체,COMMD7-shRNA조전염양성재체.전염결속후재형광현미경하관찰세포형태.채용Western blot검측COMMD7단백적표체.채용CCK-8검측세포활력,류식세포의검측세포조망.채용Western blot검측세포외조절단백격매(ERK)/사렬원활화단백격매(MAPK)신호통로중적하유분자ERK1/2화MEK1/2단백적표체급기린산화수평.부합정태분포적계량자료이(x)±s표시,다조간비교채용단인소방차분석,량량비교채용LSD-t검험.결과 형광현미경하전염성공적세포위타원형혹사형,정록색형광.Western blot검측결과현시:공백조、control-shRNA조화COMMD7-shRNA조간암세포HepG2중COMMD7단백적상대표체량분별위0.90±0.18、1.03±0.05화0.23 ±0.03,3조비교,차이유통계학의의(F=152.08,P＜0.05);COMMD7-shRNA조COMMD7단백상대표체량저우공백조화control-shRNA조,량조비교,차이유통계학의의(t=20.74,21.16,P＜0.05).CCK-8검측결과현시:공백조、control-shRNA조화COMMD7-shRNA조간암세포HepG2세포활력분별위1.193±0.024、1.225±0.034화1.147 ±0.021,3조비교,차이유통계학의의(F=6.90,P＜0.05);COMMD7-shRNA조간암세포HepG2세포활력저우공백조화control-shRNA조,량조비교,차이유통계학의의(t=3.53,3.69,P＜0.05).류식세포의검측결과현시:공백조、control-shRNA조화COMMD7-shRNA조간암세포HepG2조망솔분별위6.1％±0.3％、7.8％±0.5％화20.9％±1.4％,3조비교,차이유통계학의의(F=270.80,P＜0.05);COMMD7-shRNA조간암세포HepG2조망솔고우공백조화control-shRNA조,량조비교,차이유통계학의의(=21.77,19.36,P＜0.05).Western blot검측결과현시:공백조、control-shRNA조화COMMD7-shRNA조간암세포HepG2중린산화-ERK1/2단백상대표체량분별위0.932±0.046、0.945±0.017화0.553±0.052,린산화-MEK1/2단백상대표체량분별위0.452±0.031、0.468±0.027화0.263±0.022,3조비교,차이균유통계학의의(F =93.61,49.16,P＜0.05);COMMD7-shRNA조간암세포HepG2중린산화-ERK1/2단백상대표체량저우공백조화control-shRNA조,량조비교,차이유통계학의의(t=11.94,12.17,P＜0.05);린산화-MEK1/2단백상대표체량야저우공백조화control-shRNA조,량조비교,차이유통계학의의(=9.33,8.65,P＜0.05).결론 COMMD7기인가통과활화ERK/MAPK신호통로촉진간암세포HepG2증식,기작용궤제가능시촉진료ERK/MAPK신호통로중ERK1/2、MEK1/2적린산화.
Objective To observe the changes of the cells of human hepatocellular carcinoma (HepG2)using RNA for silencing the expression of COMMD7 gene,and investigate related mechanism of COMMD7 gene promoting HepG2 proliferation.Methods COMMD7 gene shRNA was designed and constructed into COMMD7-shRNA plasmid.HepG2 cells were divided into the HepG2 group,control-shRNA group (empty vectors were infected) and COMMD7-shRNA group (positive vectors were infected).Cells shapes were observed by fluorescence microscope after infecting.The expression of COMMD7 and expression and phosphosylation of extracellular regulated protein kinase1/2 (ERK1/2) and MEK1/2 protein were measured by Western blot.The cell vitality was measured by cholecystokinin octapeptide (CCK-8),and the apoptosis of cell was detected by flow cytometry.The measurement data with normal distribution were presented as (x) ± s.The comparisons among groups were evaluated with the one-way ANOVA,and pairwise comparison was analyzed by the LSD-t test.Results The cells were oval or spindle shapes and displayed green fluorescent after infected successfully.The results of Western blot showed that the relative quantitative expression of COMMD7 protein in the HepG2 group,control-shRNA group and COMMD7-shRNA group were 0.90 ±0.18,1.03 ±0.05 and 0.23 ±0.03,respectively,with a significant difference among the 3 groups (F =152.08,P ＜ 0.05),and the expression of COMMD7 protein in the COMMD7-shRNA group was significantly lower than those in the other 2 groups (t =20.74,21.16,P ＜ 0.05).The results of CCK-8 showed that the scores of the HepG2 vitality in the HepG2 group,control-shRNA group and COMMD7-shRNA group were 1.193 ±0.024,1.225 ±0.034 and 1.147 ±0.021,respectively,with a significant difference among the 3 groups (F =6.90,P ＜ 0.05),and the HepG2 vitality in the COMMD7-shRNA group was significantly lower than those in the other 2 groups (t =3.53,3.69,P ＜ 0.05).The results of flow cytometry showed that the apoptosis rate of HepG2 in the HepG2 group,control-shRNA group and COMMD7-shRNA group were 6.1％ ± 0.3％,7.8％ ± 0.5％ and 20.9％ ± 1.4％,showing a significant difference among the 3 groups (F =270.80,P ＜0.05),and the apoptosis rate of HepG2 in the COMMD7-shRNA group was significant higher than those in the other 2 groups (t =21.77,19.36,P ＜0.05).The results of Western blot showed that the relative quantitative expression of phosphorylation (p)-ERK1/2 and p-MEK1/2 in the HepG2 group,control-shRNA group and COMMD7-shRNA group were 0.932 ±0.046,0.945 ±0.017,0.553 ±0.052 and 0.452 ±0.031,0.468±0.027,0.263 ± 0.022,respectively,showing significant differences among the 3 groups (F =93.61,49.16,P ＜ 0.05),and the relative quantitative expression of p-ERK1/2 and p-MEK1/2 in the COMMD7-shRNA group were significantly lower than those in the other 2 groups (t =11.94,12.17,9.33,8.65,P ＜ 0.05).Conclusions COMMD7 gene can promote HepG2 proliferation via activating ERK/mitogen-activated protein kinase (MAPK) signaling pathway,and its mechanism may be promoting the phosphorylation of expression of ERK1/2 and MEK1/2.
